Vivos Therapeutics Inc. (NASDAQ: VVOS) announced a binding agreement with senior lender Streeterville Capital LLC to exchange up to $4.5 million of outstanding debt into preferred and common stock. The medical device company said the transaction aims to support its continued Nasdaq listing compliance.

Under the agreement, Streeterville committed to suspend debt repayment calls for 90 days and halt sales of company securities for 60 days once the debt-to-equity exchange becomes effective. The conversion is contingent on completion of qualifying equity financings on terms acceptable to the company.

The Colorado-based company focuses on treating breathing-related sleep disorders, including obstructive sleep apnea. In June 2025, Vivos acquired operating assets of The Sleep Center of Nevada, the state's largest operator of medical sleep centers, through debt financing from Streeterville and equity investment from a New Seneca Partners affiliate.

The debt conversion combined with contemplated equity raises is designed to improve stockholders' equity and advance the company's equity remediation plan to meet Nasdaq listing standards. The transactions would also reduce debt service obligations and support cash flows, according to the company.

Vivos noted no assurance exists that qualifying financing will be completed or that conditions for the debt exchange will be satisfied. The company's devices have received FDA clearance for treating OSA in adults and children ages 6 to 17.

The press release stated the announcement serves informational purposes only and does not constitute a securities offering solicitation.